Literature DB >> 9615772

Effect of butyrate analogues on proliferation and differentiation in human neuroblastoma cell lines.

P Rocchi1, A M Ferreri, E Magrini, P Perocco.   

Abstract

Butyric acid has been shown in vitro to produce cytodifferentiation of a wide variety of neoplastic cells. The potential clinical use of this compound as a therapeutic agent is limited by its rapid metabolism. This has led to the examination, as potential antineoplastic agents, of compounds structurally correlated to butyrate, with longer biological half lives. In this study we investigated the effect in vitro of two butyrate analogues, tributyrin and butyramide, on inducing growth inhibition and expression of morphological and immunophenotypic properties, in human neuroblastoma cell lines. Treatment with tributyrin resulted in a strong inhibition of cell proliferation and in induction of extensive differentiation; on the contrary butyramide was scarcely effective or quite ineffective. These results demonstrate that tributyrin retains the effectiveness of butyrate and suggest that this analogue could have utility for cytodifferentiation therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9615772

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors.

Authors:  Luis H Camacho; Jon Olson; William P Tong; Charles W Young; David R Spriggs; Mark G Malkin
Journal:  Invest New Drugs       Date:  2006-10-20       Impact factor: 3.850

2.  Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study.

Authors:  Danila Coradini; Cinzia Pellizzaro; Gabriella Abolafio; Marco Bosco; Ignazio Scarlata; Silvia Cantoni; Luca Stucchi; Sonia Zorzet; Claudia Turrin; Gianni Sava; Alberto Perbellini; Maria Grazia Daidone
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.